Bay City Capital Fund V, L.p. - Net Worth and Insider Trading

Bay City Capital Fund V, L.p. Net Worth

The estimated net worth of Bay City Capital Fund V, L.p. is at least $6,500 dollars as of 2024-09-20. Bay City Capital Fund V, L.p. is the 10% Owner of Interleukin Genetics Inc and owns about 1,444,485 shares of Interleukin Genetics Inc (ILIU) stock worth over $6,500. Details can be seen in Bay City Capital Fund V, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Bay City Capital Fund V, L.p. has not made any transactions after 2016-07-29 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Bay City Capital Fund V, L.p.

To

Bay City Capital Fund V, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Bay City Capital Fund V, L.p. owns 7 companies in total, including Imara Inc (IMRA) , Interleukin Genetics Inc (ILIU) , and Epizyme Inc (EPZM) among others .

Click here to see the complete history of Bay City Capital Fund V, L.p.’s form 4 insider trades.

Insider Ownership Summary of Bay City Capital Fund V, L.p.

Ticker Comapny Transaction Date Type of Owner
IMRA Imara Inc 2020-03-11 10 percent owner
ILIU Interleukin Genetics Inc 2016-07-29 10 percent owner
EPZM Epizyme Inc 2013-05-30 10 percent owner
LIMIT LIMIT 2015-07-24 10 percent owner
LIMIT LIMIT 2014-10-08 10 percent owner
LIMIT LIMIT 2015-07-24 10 percent owner
LIMIT LIMIT 2020-03-11 10 percent owner

Bay City Capital Fund V, L.p. Latest Holdings Summary

Bay City Capital Fund V, L.p. currently owns a total of 1 stock. Bay City Capital Fund V, L.p. owns 1,444,485 shares of Interleukin Genetics Inc (ILIU) as of July 29, 2016, with a value of $6,500.

Latest Holdings of Bay City Capital Fund V, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ILIU Interleukin Genetics Inc 2016-07-29 1,444,485 0.00 6,500

Holding Weightings of Bay City Capital Fund V, L.p.


Bay City Capital Fund V, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Bay City Capital Fund V, L.p. has made a total of 0 transactions in Interleukin Genetics Inc (ILIU) over the past 5 years. The most-recent trade in Interleukin Genetics Inc is the acquisition of 30,181,086 shares on July 29, 2016, which cost Bay City Capital Fund V, L.p. around $3 Million.

Insider Trading History of Bay City Capital Fund V, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Bay City Capital Fund V, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Bay City Capital Fund V, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Bay City Capital Fund V, L.p. is 25%. GuruFocus also compares Bay City Capital Fund V, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Bay City Capital Fund V, L.p. within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Bay City Capital Fund V, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Bay City Capital Fund V, L.p.

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 50 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 49.69 LIMIT LIMIT LIMIT LIMIT LIMIT

Bay City Capital Fund V, L.p. Ownership Network

Ownership Network List of Bay City Capital Fund V, L.p.

No Data

Ownership Network Relation of Bay City Capital Fund V, L.p.

Insider Network Chart

Bay City Capital Fund V, L.p. Owned Company Details

What does Imara Inc do?

Who are the key executives at Imara Inc?

Bay City Capital Fund V, L.p. is the 10 percent owner of Imara Inc. Other key executives at Imara Inc include director & President & CEO Rahul D. Ballal , See Remarks Michael Gray , and 10 percent owner Braden Michael Leonard .

Imara Inc (IMRA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Imara Inc (IMRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Imara Inc (IMRA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Imara Inc (IMRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Imara Inc Insider Transactions

No Available Data

Bay City Capital Fund V, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Bay City Capital Fund V, L.p.. You might contact Bay City Capital Fund V, L.p. via mailing address: 750 Battery Street, Suite 400, San Francisco Ca 94111.

Discussions on Bay City Capital Fund V, L.p.

No discussions yet.